Beyond GLP-1: Why Peptides Are Back at the Center of Drug Discovery with Charlie Johannes and Tomi Sawyer

About this episode

The episode discusses the resurgence of peptides in drug discovery and the challenges and advancements in the field.

Peptides are having a moment. But beneath the market excitement and the GLP-1 headlines, something more interesting is going on. A field that for years seemed technically promising but perpetually constrained is becoming wide open. To see into that open terrain, we’re joined by Charlie Johannes, founder of EPOC Scientific and president of the Peptide Drug Hunting Consortium , along with Tomi Sawyer, a founder of the Consortium and founder of Maestro Therapeutics. We asked them for a high-level look at a field being reshaped by advances in chemistry, screening, delivery, and by a growing sense that peptides may be uniquely positioned to open up biology that other modalities have only partly been able to reach. And yet both are clear: the field is not mature. AI is accelerating biology, which still depends on existing knowledge. Prediction remains limited, especially with non-natural chemistry. And the core challenge may now be human—how to turn an overwhelming amount of data into real innovation. As Johannes puts it, “Turning knowledge into innovation is the real challenge.” Chapters: 1:31 Why peptides are suddenly hot again6:10 Between small molecules and biologics10:14 Oral…

People in this episode

Host: Theral Timpson

Guests: Charlie Johannes, Tomi Sawyer

Topics covered

• peptides
• drug discovery
• AI in biology
• chemistry advances
• biologics
• oral delivery

Keywords

• peptides
• drug discovery
• GLP-1
• AI
• chemistry
• biologics
• innovation

Mentioned in this episode

Organizations: EPOC Scientific, Peptide Drug Hunting Consortium, Maestro Therapeutics

More episodes of Mendelspod Podcast

• Gary Schroth on Connecting Cellular Behavior to the Transcriptome · June 11, 2026 · 33 min
• Two-Thirds of High-Risk Breast Cancer Patients May Avoid Chemotherapy According to Veracyte Data Presented at ASCO · June 9, 2026 · 27 min
• Building the Diagnostic Layer of Modern Cancer Care with Rita Shaknovich and Karina Kulangara of Agilent · May 29, 2026 · 32 min
• Mapping the Multi-Omic Era with Eric Green of Illumina · May 28, 2026 · 44 min
• Inside Proteomics at Thermo Fisher with Yan Zhang · May 21, 2026 · 5 min
• Separating Epigenetic Signals Improves Early Cancer Detection with Rob Osborne, Biomodal · May 19, 2026 · 23 min